Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors

Fig. 6

Swimmer plot showing the interval between increase of the BRAF V600mut ctDNA fraction and progressive disease according to RECIST v1.1 on imaging (PD), for all 36 patients patients from start of ctDNA monitoring. In 12 patients, an increase in the BRAF V600mut ctDNA fraction was detected prior to PD. In 7 patients, an increase of the BRAF V600mut ctDNA fraction was detected simultaneously with PD. In 8 patients, no increase in the BRAF V600mut ctDNA fraction was detected prior to or simultaneously with PD. None of the patients with an ongoing response showed an increase of the BRAF V600mut ctDNA fraction

Back to article page